Loading…
Role of genetically engineered mesenchymal stem cell exosomes and LncRNAs in respiratory diseases treatment
The term acute respiratory disease encompasses a wide range of acute lung diseases, which in recent years have been ranked among the top three deadly diseases in the world. Since conventional treatment methods, including the use of anti-inflammatory drugs, have had no significant effect on the treat...
Saved in:
Published in: | Pathology, research and practice research and practice, 2024-02, Vol.254, p.155135-155135, Article 155135 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c305t-d6a8172f912863adbf496c18837da3e055f82cfce38de7bb4f5071aa95abb263 |
container_end_page | 155135 |
container_issue | |
container_start_page | 155135 |
container_title | Pathology, research and practice |
container_volume | 254 |
creator | Jasim, Saade Abdalkareem Aziz, Dhifaf Zeki Mustafa, Yasser Fakri Margiana, Ria Al-Alwany, Ameen Abdulhasan Hjazi, Ahmed Alawadi, Ahmed Yumashev, Alexey Alsalamy, Ali Fenjan, Mohammed N. |
description | The term acute respiratory disease encompasses a wide range of acute lung diseases, which in recent years have been ranked among the top three deadly diseases in the world. Since conventional treatment methods, including the use of anti-inflammatory drugs, have had no significant effect on the treatment process of these diseases, the attention of the medical community has been drawn to alternative methods. Mesenchymal stem cells (MSC) are multipotential stem/progenitor cells that have extensive immunomodulatory and anti-inflammatory properties and also play a critical role in the microenvironment of injured tissue. MSC secretomes (containing large extracellular vesicles, microvesicles, and exosomes) are a newly introduced option for cell-free therapies that can circumvent the hurdles of cell-based therapies while maintaining the therapeutic role of MSC themselves. The therapeutic capabilities of MSCs have been showed in many acute respiratory diseases, including chronic respiratory disease (CRD), novel coronavirus 2019 (COVID −19), and pneumonia. MSCs offer novel therapeutic approaches for chronic and acute lung diseases due to their anti-inflammatory and immunomodulatory properties. In this review, we summarize the current evidence on the efficacy and safety of MSC-derived products in preclinical models of lung diseases and highlight the biologically active compounds present in the MSC secretome and their mechanisms involved in anti-inflammatory activity and tissue regeneration. |
doi_str_mv | 10.1016/j.prp.2024.155135 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2921114962</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0344033824000463</els_id><sourcerecordid>2921114962</sourcerecordid><originalsourceid>FETCH-LOGICAL-c305t-d6a8172f912863adbf496c18837da3e055f82cfce38de7bb4f5071aa95abb263</originalsourceid><addsrcrecordid>eNp9kE1v1DAQhi1ERZe2P4AL8pFLFo8dJ444VRVf0opKVe-WY0-Kl8QOthex_x6vtnDkNNLMM69mHkLeANsCg-79frumdcsZb7cgJQj5gmygA9WwTsBLsmGibRsmhLokr3PeM8Z61sIrcikUH2TbwYb8eIgz0jjRJwxYvDXzfKQYnnxATOjoghmD_X5czExzwYVanGeKv2OOdURNcHQX7MO320x9oAnz6pMpMR2p8xlNrkxJaMqCoVyTi8nMGW-e6xV5_PTx8e5Ls7v__PXudtdYwWRpXGcU9HwagKtOGDdO7dBZUEr0zghkUk6K28miUA77cWwnyXowZpBmHHknrsi7c-ya4s8D5qIXn09nm4DxkDUfOADUTF5ROKM2xZwTTnpNfjHpqIHpk2K9r51VnxTrs-K68_Y5_jAu6P5t_HVagQ9nAOuPvzwmna2vEtH5hLZoF_1_4v8ABtKOFA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2921114962</pqid></control><display><type>article</type><title>Role of genetically engineered mesenchymal stem cell exosomes and LncRNAs in respiratory diseases treatment</title><source>ScienceDirect Journals</source><creator>Jasim, Saade Abdalkareem ; Aziz, Dhifaf Zeki ; Mustafa, Yasser Fakri ; Margiana, Ria ; Al-Alwany, Ameen Abdulhasan ; Hjazi, Ahmed ; Alawadi, Ahmed ; Yumashev, Alexey ; Alsalamy, Ali ; Fenjan, Mohammed N.</creator><creatorcontrib>Jasim, Saade Abdalkareem ; Aziz, Dhifaf Zeki ; Mustafa, Yasser Fakri ; Margiana, Ria ; Al-Alwany, Ameen Abdulhasan ; Hjazi, Ahmed ; Alawadi, Ahmed ; Yumashev, Alexey ; Alsalamy, Ali ; Fenjan, Mohammed N.</creatorcontrib><description>The term acute respiratory disease encompasses a wide range of acute lung diseases, which in recent years have been ranked among the top three deadly diseases in the world. Since conventional treatment methods, including the use of anti-inflammatory drugs, have had no significant effect on the treatment process of these diseases, the attention of the medical community has been drawn to alternative methods. Mesenchymal stem cells (MSC) are multipotential stem/progenitor cells that have extensive immunomodulatory and anti-inflammatory properties and also play a critical role in the microenvironment of injured tissue. MSC secretomes (containing large extracellular vesicles, microvesicles, and exosomes) are a newly introduced option for cell-free therapies that can circumvent the hurdles of cell-based therapies while maintaining the therapeutic role of MSC themselves. The therapeutic capabilities of MSCs have been showed in many acute respiratory diseases, including chronic respiratory disease (CRD), novel coronavirus 2019 (COVID −19), and pneumonia. MSCs offer novel therapeutic approaches for chronic and acute lung diseases due to their anti-inflammatory and immunomodulatory properties. In this review, we summarize the current evidence on the efficacy and safety of MSC-derived products in preclinical models of lung diseases and highlight the biologically active compounds present in the MSC secretome and their mechanisms involved in anti-inflammatory activity and tissue regeneration.</description><identifier>ISSN: 0344-0338</identifier><identifier>EISSN: 1618-0631</identifier><identifier>DOI: 10.1016/j.prp.2024.155135</identifier><identifier>PMID: 38295461</identifier><language>eng</language><publisher>Germany: Elsevier GmbH</publisher><subject>Cell-free therapies ; Immunomodulation ; Inflammation ; Mesenchymal stem cell ; Respiratory disease ; Tissue regeneration</subject><ispartof>Pathology, research and practice, 2024-02, Vol.254, p.155135-155135, Article 155135</ispartof><rights>2024 Elsevier GmbH</rights><rights>Copyright © 2024 Elsevier GmbH. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c305t-d6a8172f912863adbf496c18837da3e055f82cfce38de7bb4f5071aa95abb263</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38295461$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jasim, Saade Abdalkareem</creatorcontrib><creatorcontrib>Aziz, Dhifaf Zeki</creatorcontrib><creatorcontrib>Mustafa, Yasser Fakri</creatorcontrib><creatorcontrib>Margiana, Ria</creatorcontrib><creatorcontrib>Al-Alwany, Ameen Abdulhasan</creatorcontrib><creatorcontrib>Hjazi, Ahmed</creatorcontrib><creatorcontrib>Alawadi, Ahmed</creatorcontrib><creatorcontrib>Yumashev, Alexey</creatorcontrib><creatorcontrib>Alsalamy, Ali</creatorcontrib><creatorcontrib>Fenjan, Mohammed N.</creatorcontrib><title>Role of genetically engineered mesenchymal stem cell exosomes and LncRNAs in respiratory diseases treatment</title><title>Pathology, research and practice</title><addtitle>Pathol Res Pract</addtitle><description>The term acute respiratory disease encompasses a wide range of acute lung diseases, which in recent years have been ranked among the top three deadly diseases in the world. Since conventional treatment methods, including the use of anti-inflammatory drugs, have had no significant effect on the treatment process of these diseases, the attention of the medical community has been drawn to alternative methods. Mesenchymal stem cells (MSC) are multipotential stem/progenitor cells that have extensive immunomodulatory and anti-inflammatory properties and also play a critical role in the microenvironment of injured tissue. MSC secretomes (containing large extracellular vesicles, microvesicles, and exosomes) are a newly introduced option for cell-free therapies that can circumvent the hurdles of cell-based therapies while maintaining the therapeutic role of MSC themselves. The therapeutic capabilities of MSCs have been showed in many acute respiratory diseases, including chronic respiratory disease (CRD), novel coronavirus 2019 (COVID −19), and pneumonia. MSCs offer novel therapeutic approaches for chronic and acute lung diseases due to their anti-inflammatory and immunomodulatory properties. In this review, we summarize the current evidence on the efficacy and safety of MSC-derived products in preclinical models of lung diseases and highlight the biologically active compounds present in the MSC secretome and their mechanisms involved in anti-inflammatory activity and tissue regeneration.</description><subject>Cell-free therapies</subject><subject>Immunomodulation</subject><subject>Inflammation</subject><subject>Mesenchymal stem cell</subject><subject>Respiratory disease</subject><subject>Tissue regeneration</subject><issn>0344-0338</issn><issn>1618-0631</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kE1v1DAQhi1ERZe2P4AL8pFLFo8dJ444VRVf0opKVe-WY0-Kl8QOthex_x6vtnDkNNLMM69mHkLeANsCg-79frumdcsZb7cgJQj5gmygA9WwTsBLsmGibRsmhLokr3PeM8Z61sIrcikUH2TbwYb8eIgz0jjRJwxYvDXzfKQYnnxATOjoghmD_X5czExzwYVanGeKv2OOdURNcHQX7MO320x9oAnz6pMpMR2p8xlNrkxJaMqCoVyTi8nMGW-e6xV5_PTx8e5Ls7v__PXudtdYwWRpXGcU9HwagKtOGDdO7dBZUEr0zghkUk6K28miUA77cWwnyXowZpBmHHknrsi7c-ya4s8D5qIXn09nm4DxkDUfOADUTF5ROKM2xZwTTnpNfjHpqIHpk2K9r51VnxTrs-K68_Y5_jAu6P5t_HVagQ9nAOuPvzwmna2vEtH5hLZoF_1_4v8ABtKOFA</recordid><startdate>202402</startdate><enddate>202402</enddate><creator>Jasim, Saade Abdalkareem</creator><creator>Aziz, Dhifaf Zeki</creator><creator>Mustafa, Yasser Fakri</creator><creator>Margiana, Ria</creator><creator>Al-Alwany, Ameen Abdulhasan</creator><creator>Hjazi, Ahmed</creator><creator>Alawadi, Ahmed</creator><creator>Yumashev, Alexey</creator><creator>Alsalamy, Ali</creator><creator>Fenjan, Mohammed N.</creator><general>Elsevier GmbH</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202402</creationdate><title>Role of genetically engineered mesenchymal stem cell exosomes and LncRNAs in respiratory diseases treatment</title><author>Jasim, Saade Abdalkareem ; Aziz, Dhifaf Zeki ; Mustafa, Yasser Fakri ; Margiana, Ria ; Al-Alwany, Ameen Abdulhasan ; Hjazi, Ahmed ; Alawadi, Ahmed ; Yumashev, Alexey ; Alsalamy, Ali ; Fenjan, Mohammed N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c305t-d6a8172f912863adbf496c18837da3e055f82cfce38de7bb4f5071aa95abb263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Cell-free therapies</topic><topic>Immunomodulation</topic><topic>Inflammation</topic><topic>Mesenchymal stem cell</topic><topic>Respiratory disease</topic><topic>Tissue regeneration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jasim, Saade Abdalkareem</creatorcontrib><creatorcontrib>Aziz, Dhifaf Zeki</creatorcontrib><creatorcontrib>Mustafa, Yasser Fakri</creatorcontrib><creatorcontrib>Margiana, Ria</creatorcontrib><creatorcontrib>Al-Alwany, Ameen Abdulhasan</creatorcontrib><creatorcontrib>Hjazi, Ahmed</creatorcontrib><creatorcontrib>Alawadi, Ahmed</creatorcontrib><creatorcontrib>Yumashev, Alexey</creatorcontrib><creatorcontrib>Alsalamy, Ali</creatorcontrib><creatorcontrib>Fenjan, Mohammed N.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pathology, research and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jasim, Saade Abdalkareem</au><au>Aziz, Dhifaf Zeki</au><au>Mustafa, Yasser Fakri</au><au>Margiana, Ria</au><au>Al-Alwany, Ameen Abdulhasan</au><au>Hjazi, Ahmed</au><au>Alawadi, Ahmed</au><au>Yumashev, Alexey</au><au>Alsalamy, Ali</au><au>Fenjan, Mohammed N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of genetically engineered mesenchymal stem cell exosomes and LncRNAs in respiratory diseases treatment</atitle><jtitle>Pathology, research and practice</jtitle><addtitle>Pathol Res Pract</addtitle><date>2024-02</date><risdate>2024</risdate><volume>254</volume><spage>155135</spage><epage>155135</epage><pages>155135-155135</pages><artnum>155135</artnum><issn>0344-0338</issn><eissn>1618-0631</eissn><abstract>The term acute respiratory disease encompasses a wide range of acute lung diseases, which in recent years have been ranked among the top three deadly diseases in the world. Since conventional treatment methods, including the use of anti-inflammatory drugs, have had no significant effect on the treatment process of these diseases, the attention of the medical community has been drawn to alternative methods. Mesenchymal stem cells (MSC) are multipotential stem/progenitor cells that have extensive immunomodulatory and anti-inflammatory properties and also play a critical role in the microenvironment of injured tissue. MSC secretomes (containing large extracellular vesicles, microvesicles, and exosomes) are a newly introduced option for cell-free therapies that can circumvent the hurdles of cell-based therapies while maintaining the therapeutic role of MSC themselves. The therapeutic capabilities of MSCs have been showed in many acute respiratory diseases, including chronic respiratory disease (CRD), novel coronavirus 2019 (COVID −19), and pneumonia. MSCs offer novel therapeutic approaches for chronic and acute lung diseases due to their anti-inflammatory and immunomodulatory properties. In this review, we summarize the current evidence on the efficacy and safety of MSC-derived products in preclinical models of lung diseases and highlight the biologically active compounds present in the MSC secretome and their mechanisms involved in anti-inflammatory activity and tissue regeneration.</abstract><cop>Germany</cop><pub>Elsevier GmbH</pub><pmid>38295461</pmid><doi>10.1016/j.prp.2024.155135</doi><tpages>1</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0344-0338 |
ispartof | Pathology, research and practice, 2024-02, Vol.254, p.155135-155135, Article 155135 |
issn | 0344-0338 1618-0631 |
language | eng |
recordid | cdi_proquest_miscellaneous_2921114962 |
source | ScienceDirect Journals |
subjects | Cell-free therapies Immunomodulation Inflammation Mesenchymal stem cell Respiratory disease Tissue regeneration |
title | Role of genetically engineered mesenchymal stem cell exosomes and LncRNAs in respiratory diseases treatment |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T19%3A18%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20genetically%20engineered%20mesenchymal%20stem%20cell%20exosomes%20and%20LncRNAs%20in%20respiratory%20diseases%20treatment&rft.jtitle=Pathology,%20research%20and%20practice&rft.au=Jasim,%20Saade%20Abdalkareem&rft.date=2024-02&rft.volume=254&rft.spage=155135&rft.epage=155135&rft.pages=155135-155135&rft.artnum=155135&rft.issn=0344-0338&rft.eissn=1618-0631&rft_id=info:doi/10.1016/j.prp.2024.155135&rft_dat=%3Cproquest_cross%3E2921114962%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c305t-d6a8172f912863adbf496c18837da3e055f82cfce38de7bb4f5071aa95abb263%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2921114962&rft_id=info:pmid/38295461&rfr_iscdi=true |